Cross-Cultural Use of Performance-Based Functional Assessment in Alzheimer's Disease

Inclusion criteria

• Persons with age-related MCI or AD according to clinical diagnosis, consistent with National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria
• Community-dwelling controls
• Age > 55 years
• Have been enrolled and completed at least one visit in the Bio-AD study and consent to access their data (the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376))
• Have capacity to provide consent; capacity will be assessed at the time of consent
• Ability to complete baseline assessments
• Has informant (study partner) available to complete functional interviews/survey measures

Exclusion criteria

• Presence of concomitant medical, neurological, or psychiatric illness or condition that in the opinion of the investigators would confound interpretation of study results. These include:
• Korsakoff encephalopathy;
• active substance abuse;
• hepatitis C;
• opportunistic brain infection;
• brain tumor;
• active neoplastic disease (skin tumors other than melanoma are not exclusionary; participants with stable prostate cancer may be included at the discretion of the project director);
• multiple sclerosis;
• history of clinically significant stroke;
• current evidence or history in the past 2 years of

• focal brain lesion,
• head injury with loss of consciousness in the past year, or
• DSM-5 criteria for any major psychiatric disorder, including

• psychosis,
• uncontrolled major depression,
• bipolar disorder,
• alcohol or substance abuse;
• blindness,
• deafness or
• any other disability which may prevent the participant from participating or cooperating in the protocol.
• Prisoners
• Any contraindication for MRI